Prismatic Bio
Prismatic Bio is building an automation platform for biology's most complex assays, targeting the workflows that current tools cannot handle effectively. The platform is designed to reduce manual intervention and variability in assay processes, improving reproducibility and throughput for advanced therapy development. The company is actively engaging with potential partners and early adopters to ensure the platform addresses real-world needs in biotech and pharmaceutical manufacturing.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Many advanced therapies rely on complex biological assays that are difficult to automate and scale, creating bottlenecks in development and manufacturing. These hard-to-scale processes limit patient access to new treatments and slow the path from research to clinical application.
Solution
Prismatic Bio is building an automation platform specifically designed to tackle biology's most challenging assays. By automating these complex workflows, the platform aims to remove key bottlenecks in therapy development and production, making new and hard-to-scale therapies more accessible to patients. The platform is engineered to reduce manual intervention and variability in assay processes, improving reproducibility and throughput for workflows that current tools cannot handle effectively. The company is actively developing the platform and engaging with potential partners and early adopters to ensure it addresses real-world needs in advanced therapy development.
Target Audience
Prismatic Bio's primary customers are biotech and pharmaceutical companies developing advanced therapies that depend on complex, hard-to-scale biological assays, as well as research organizations seeking to automate challenging experimental workflows.
Features
- Automation platform engineered for high-complexity biological assays that are difficult to scale with existing tools
- Focus on workflows associated with new and emerging therapies, addressing a critical gap in current biotech infrastructure
- Designed to reduce manual intervention and variability in assay processes, improving reproducibility and throughput
- Early-stage platform development informed by direct engagement with potential partners and early-access users